Pharma BD Deal Intelligence
AbbVie acquired Aliada Therapeutics for $1.4B for neuroscience pipeline.
AbbVie adds another Alzheimer's prospect with $1.4B Aliada Therapeutics acquisition leveraging blood-brain barrier crossing technology.
AbbVie signs agreement to acquire Aliada for $1.4 billion for Alzheimer and neuroscience pipeline.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie acquired Aliada Therapeutics for $1.4B for neuroscience pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Aliada Therapeutics (this deal) | 2024 | $1.4B | 52 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Neurology deals